Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Mar;139(3):237-247.
doi: 10.1111/acps.12989. Epub 2018 Dec 16.

Clozapine and all-cause mortality in treatment-resistant schizophrenia: a historical cohort study

J Cho  1 , R D Hayes  1   2 , A Jewell  3 , G Kadra  1 , H Shetty  1   2   3 , J H MacCabe  1   2   3 , J Downs  1   2   3
Affiliations

Clozapine and all-cause mortality in treatment-resistant schizophrenia: a historical cohort study

J Cho et al. Acta Psychiatr Scand. 2019 Mar.

Abstract

Objective: Large-scale epidemiological studies have demonstrated a protective effect of clozapine on mortality in people with schizophrenia. Clozapine is reserved for use in patients with treatment-resistant schizophrenia (TRS), but evidence of clozapine's effect on mortality exclusively within TRS samples is inconclusive. Hence, we aimed to investigate the effect of clozapine use on all-cause mortality in TRS patients.

Methods: A historical patient cohort sample of 2837 patients, who met criteria for TRS between 1 Jan 2008 and 1 Jan 2016, were selected from the South London and Maudsley NHS Foundation Trust (SLAM) electronic health records (EHR). The national Zaponex Treatment Access System (ZTAS) mandatory monitoring system linked to the SLAM EHR was used to distinguish which patients were initiated on clozapine (n = 1025). Cox proportional hazard models were used, adjusting for sociodemographics, clinical monitoring, mental and physical illness severity and functional status.

Results: After controlling for potential confounders, the protective effect of clozapine on all-cause mortality was significant (adjusted hazard ratio 0.61; 95% confidence interval 0.38-0.97; P = 0.04).

Conclusions: Clozapine reduces the risk of mortality in patients who meet criteria for TRS. We provide further evidence that improving access to clozapine in TRS is likely to reduce the mortality gap in schizophrenia.

Keywords: clozapine; mortality; schizophrenia; treatment-resistant.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Selection of study subjects.
Figure 2
Figure 2
Survival curves of all‐cause mortality in patients with treatment‐resistant schizophrenia, stratified by antipsychotic use.
See this image and copyright information in PMC

References

    1. Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry 2007;64:1123–1131. - PubMed
    1. Hayes RD, Downs J, Chang C‐K et al. The effect of clozapine on premature mortality: an assessment of clinical monitoring and other potential confounders. Schizophr Bull 2015;41:644–655. - PMC - PubMed
    1. Kelly DL, McMahon RP, Liu F et al. Cardiovascular disease mortality in patients with chronic schizophrenia treated with clozapine: a retrospective cohort study. J Clin Psychiatry 2010;71:304–311. - PMC - PubMed
    1. Kiviniemi M, Suvisaari J, Koivumaa‐Honkanen H, Häkkinen U, Isohanni M, Hakko H. Antipsychotics and mortality in first‐onset schizophrenia: prospective Finnish register study with 5‐year follow‐up. Schizophr Res 2013;150:274–280. - PubMed
    1. Sernyak MJ, Desai R, Stolar M, Rosenheck R. Impact of clozapine on completed suicide. Am J Psychiatry 2001;158:931–937. - PubMed

Publication types